Menu
Recruiting NCT07096999

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

— Observational Metastatic Castration-Resistant Prostate Carcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Non-Interventional Study.
Who it may be relevant to
Registry conditions: Metastatic Castration-Resistant Prostate Carcinoma. Basic parameters: from 18 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Interventions

  • Other Non-Interventional Study
    Non-interventional study

Primary outcome measures

  • Response and toxicity following 177Lu-RLT [Time frame: Up to 4 years]
Secondary outcome measures (1)
  • Build and test models [Time frame: Up to 4 years]

Eligibility criteria

Inclusion criteria

  • \* 177Lu-617 PSMA treatment scheduled for mCRPC
  • Clinically stable as determined by the nuclear medicine clinicians
  • Male
  • ≥ 18 years of age
  • Willing and able to provide informed consent

Exclusion criteria

  • Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • University of Michigan Comprehensive Cancer Center — Ann Arbor

Identifiers

NCT: NCT07096999 · UMCC 2024.070 · NCI-2025-01555 · HUM00257753 · R01CA289631

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗